Physician profile

Anthony J Stephens

Neurology (Psychiatry & Neurology) · Crest Hill, IL

NPI 1831184431

$3,995.64

in general payments reported to CMS, 2019-2025

26 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Livanova USA, INC. $1,280.21 2019
Alexion Pharmaceuticals, INC. $390.78 2019-2020
Teva Pharmaceuticals USA, INC. $303.47 2019-2020
Ucb, INC. $297.90 2019-2020
Novartis Pharmaceuticals Corporation $235.81 2019
Biogen, INC. $204.61 2019-2020
Supernus Pharmaceuticals, INC. $196.07 2019-2020
Neurocrine Biosciences, INC. $167.97 2019-2020
Genentech USA, INC. $141.77 2019-2020
Lundbeck LLC $106.35 2019-2020
Lilly USA, LLC $85.66 2019-2020
Acadia Pharmaceuticals INC $83.88 2019-2021
Arbor Pharmaceuticals, INC. $72.76 2019-2020
Amneal Pharmaceuticals LLC $64.59 2019-2020
Zyla Life Sciences, INC. $55.54 2019-2020
Show all 26 companies
CompanyGeneral paymentsYearsTop products
Csl Behring $48.33 2019-2020
Genzyme Corporation $47.82 2019-2020
Mallinckrodt Enterprises LLC $42.43 2019
Emd Serono, INC. $36.54 2019
Grifols USA, LLC $31.66 2019
Amgen INC. $21.03 2019
Mdd US Operations, LLC $20.09 2020
Pfizer INC. $16.79 2019
Abbvie INC. $16.43 2019
Vertical Pharmaceuticals, LLC $14.18 2019
Bayer Healthcare Pharmaceuticals INC. $12.97 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anthony J Stephens

$3,995.64

in general payments reported 2019-2025

Years
2019-2021
Top company
Livanova USA, INC.

https://glasscript.com/doctor/82732/anthony-j-stephens

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.